GT Medical Technologies Completes Oversubscribed $100 Million Series E Equity Financing to Advance Commercial Treatment for Patients with Operable Brain Tumors

GT Medical Technologies, Inc. has successfully closed an oversubscribed $100 million Series E equity financing, which was led by new investor Viking Global Investors. The financing round, announced on June 9, 2026, also saw participation from existing investors including MVM Partners, Gilde Healthcare, Evidity Health Capital, Medtech Venture Partners, and FemHealth Ventures. The funds raised will primarily be directed towards enhancing the company’s commercial treatment capabilities for operable brain tumors.

Founded to address significant unmet needs in brain tumor treatment, GT Medical Technologies is known for its innovative GammaTile therapy, a bioresorbable radiotherapy implant designed to deliver immediate, targeted radiation at the tumor resection site during surgery. This approach minimizes the treatment gap commonly observed in conventional therapies, which typically require a delay between surgery and the initiation of radiation therapy. The recent data from the company's ROADS randomized controlled trial (RCT) has demonstrated GammaTile's potential to significantly improve patient outcomes, showing a 93% reduction in the risk of tumor recurrence and a 41% reduction in mortality at the 12-month mark compared to standard care.

The strategic rationale behind this financing is underscored by the promising clinical data that supports GammaTile's efficacy. The results from the ROADS RCT, which were presented at the 2026 American Society of Clinical Oncology (ASCO) conference, highlighted a dramatic decrease in surgical bed recurrence rates with GammaTile, further validating its potential to become a standard of care for patients with newly diagnosed brain metastases. The financing will also support the expansion of GT Medical Technologies' ongoing BRIDGES RCT, which focuses on glioblastoma patients, thereby broadening the scope of its clinical impact.

The participation of established investors alongside Viking Global Investors indicates strong confidence in GT Medical Technologies' growth trajectory and the potential of its technology. The oversubscribed nature of the financing round suggests a robust interest from the investment community in the medical devices sector, particularly in innovative solutions that address critical healthcare challenges. This capital influx will enable GT Medical Technologies to accelerate its operational initiatives, further solidifying its position in the competitive landscape of brain tumor treatment.

As the medical devices sector continues to evolve, the successful fundraising by GT Medical Technologies reflects broader trends in healthcare investment, where innovative therapies that demonstrate clinical efficacy are increasingly attracting significant capital. The ongoing focus on improving patient outcomes through advanced medical technologies is likely to drive further investments in this space, fostering a conducive environment for growth and innovation in the treatment of complex conditions such as brain tumors.